Patterns of in-stent restenosis after carotid artery stenting: Classification and implications for long-term outcome  by Lal, Brajesh K. et al.
CLINICAL RESEARCH STUDIES
From the Society for Vascular Surgery
Patterns of in-stent restenosis after carotid artery
stenting: Classification and implications for long-
term outcome
Brajesh K. Lal, MD,a,b,c,d Elias A. Kaperonis, MD,e Salvador Cuadra, MD,a,d Indravadan Kapadia, PA,d
and Robert W. Hobson II, MD,a,b,d Newark, NJ, and Athens, Greece
Objectives: Factors predicting in-stent restenosis (ISR) and future need for target lesion revascularization (TLR) after
carotid artery stenting (CAS) remain undetermined. We hypothesized that the patterns of restenotic lesions may provide
prognostic information. In this study, we developed an ultrasound classification scheme for ISR based on lesion length
and distribution and assessed factors that may predict the need for TLR.
Methods: Patients were followed up after CAS with B-mode ultrasound imaging, and ISR lesions (>40% stenosis) were
classified into type I (focal <10 mm end-stent lesions), II (focal <10 mm, intrastent), III (diffuse >10 mm, intrastent),
IV (diffuse>10mm proliferative, extending outside the stent), and V (total occlusion). The frequency of lesion types was
assessed. Accuracy of the ultrasound classification was confirmed with angiography. We recorded patient (age, gender,
comorbidities), lesion (severity, etiology, symptomatic status) and procedural features (type, number, length of stents),
and the need for TLR.
Results: Eighty-five ISR lesions developed after 255 CAS procedures. Their percentage distribution was type I, 40; type
II, 25.9; type III, 12.9; for type IV, 20; and type V, 1.2. Accuracy of the ultrasound classification was confirmed by
angiography (r2  0.82). Inter-rater agreement for the assignment of lesion type based on ultrasound was 0.88 (very
good). TLR was performed in 13 that were >80% diameter reducing. On univariate analysis, the need for TLR was
highest in type IV lesions (0%, 0%, 27.3%, and 58.8% [types I to IV, respectively]; P  .001). History of ISR (2.9%, 0%,
0%, and 41.2% [types I to IV]; P .003) and diabetes mellitus (20.6%, 22.7%, 45.5%, and 52.9% [types I to IV]; P .02)
occurred more frequently with type IV ISR lesions. On multivariate analysis of all patient, lesion, and procedural
characteristics, only the type of ISR (odds ratio, 5.1) and a history of diabetes (odds ratio, 9.7) were independent
predictors of TLR.
Conclusions: The proposed classification accurately grades the magnitude of intimal hyperplasia after CAS and provides
important prognostic information. Diffuse proliferative (type IV) ISR lesions and diabetes are important determinants of
long-term outcome after CAS. This classification will facilitate a standardized description of recurrence after CAS and
enable early identification of high-risk patients for additional monitoring, treatment, and investigation. (J Vasc Surg
2007;46:833-40.)Carotid artery stenting (CAS) has emerged as a less
invasive alternative to carotid endarterectomy (CEA) for
revascularization of extracranial carotid occlusive disease.
Our institution1-5 and others6-10 have reported that CAS
can be performed with low periprocedural morbidity. On
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doi:10.1016/j.jvs.2007.07.022long-term follow-up, we have observed in-stent restenosis
(ISR) of40% diameter reduction in 42.7% of our patients,
and of 60% diameter reduction in 16.4% at 5 years of
follow-up.5 Similarly, the Stenting and Angioplasty with
Protection in Patients at High Risk for Endarterectomy
(SAPPHIRE) investigators reported ISR in 19.7% of pa-
tients at 1 year of follow-up.11 Therefore, ISR will become
increasingly prevalent due to the exponential increase in the
use of carotid stents.
Post-CAS ISR is currently treated at a threshold of
80% diameter reduction (6.4% incidence at 5 years5).
However, factors that predict target vessel failure remain
undetermined. Primary stenting prevents carotid artery
recoil and constrictive remodeling.12 Post-CAS ISR can
threfore be primarily attributed to neointimal hyperpla-
sia,12,13 and studies of coronary ISR indicate that long
neointimal hyperplasia lesions diffusely involving the stent
surface correlate with the highest recurrence and reinter-
vention rates.14
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stenting have not been described, and their prognostic
utility has not been studied. We therefore developed an
ultrasound classification scheme for post-CAS ISR based on
the length and distribution of the lesion with respect to the
stent and verified its accuracy with carotid angiography. We
then assessed long-term clinical follow-up to determine
whether the classification system predicted the need for
future therapeutic reintervention in the form of target
lesion-site revascularization (TLR).
METHODS
Patient population and treatment. We performed
255 CAS procedures from January 1, 1996, through De-
cember 31, 2006. Lesions were treated with a WallStent
(Boston Scientific Corp, Natick, Mass) or ACCULINK
stent (Guidant Corp, St. Paul, Minn). Procedural details
for CAS at our institution have been published in detail by
our group previously.1-5
All patients received aspirin (325 mg daily) and clopi-
dogrel (75 mg twice daily) for at least 48 hours before the
procedure. Clopidogrel (75 mg daily) was continued for 30
days after the procedure, and aspirin was continued indefi-
nitely.
Patients early in our experience underwent CAS with-
out embolic protection. The ACCUNET (Abbot, Menlo
Park, Calif) antiembolic device was used in all subsequent
patients. At last follow-up, 85 arteries developed ISR of
40% and constitute the cohort for the current study.
Patients underwent endovascular retreatment when
their ISR reached a threshold of 80%, regardless of neu-
rologic symptoms. Devices used to treat ISR included
balloon angioplasty, cutting balloon angioplasty, and re-
stenting and were selected at the discretion of the treating
physician. No patient required surgical revascularization for
ISR. Lesions after the first recurrence were excluded from
the primary analysis to avoid introducing any statistical bias
in the multivariate model.
Demographics and follow-up. Clinical demograph-
ics and laboratory results were collected in a prospective
registry. Risk factors that were tabulated included coronary
artery disease (currently or previously symptomatic, requir-
ing intervention), medically treated diabetes mellitus, med-
ically treated hypertension, medically treated hypercholes-
terolemia (or if serum cholesterol was 180 mg/dL), and
smoking (current or prior smoker). Clinical follow-up was
performed with office visits and duplex ultrasound exami-
nations. The occurrence of TLR events was recorded.
Ultrasound examination. Duplex ultrasound exami-
nations, including Doppler velocity measurements and B-
mode imaging studies, were performed in our noninvasive
vascular laboratory, which is approved by the Inter-societal
Commission on Accreditation of Vascular Laboratories,15
before and after CAS within 3 days of the procedure and
during each annual follow-up visit. The studies were per-
formed with a 7-13 MHz linear array transducer (Sequoia
512, Acuson, Mountain View, Calif). Doppler velocities
were obtained with appropriate angle correction accordingto standard techniques used by our group previously4,5,16
to estimate the degree of stenosis. Velocity criteria for
native carotid arteries (peak systolic velocity 130 cm/s)
were used to identify potential patients with ISR. These
underwent detailed B-mode imaging with power Doppler
to select arteries with any ISR 40%. These lesions were
finally included in the present analysis; therefore, only
patients with confirmed visible restenotic lesions were in-
cluded in the study. This strategy ensured that we did not
miss any patients with ISR.
B-mode imaging studies during follow-up were further
used to define the morphology of the ISR lesions according
to the length and distribution of the lesion with respect to
the stent. Standard imaging techniques used previously by
our group were applied to obtain grayscale images of the
ipsilateral cervical carotid artery.5 The transducer was
placed directly over the stented carotid artery segment to
obtain a longitudinal image. It was then swept from the
base of the neck to the angle of the mandible to obtain
multiple cross-sectional images of the entire common and
internal carotid arteries. The images were recorded on
magneto-optical (MO) disks and analyzed off-line with a
computer-assisted image-analysis program (Metamorph
6.1, Universal Imaging Corp, Downingtown, Pa) by inde-
pendent observers blinded to clinical findings. The longi-
tudinal image was used to measure the length of the lesion,
defined as the distance from the proximal shoulder to the
distal shoulder of the lesion, and to determine its location
with respect to the stent. The cross-sectional views were
used to determine the luminal diameters.
Classification of in-stent restenosis. B-mode images
in longitudinal and serial cross sections were reviewed by
two independent observers who classified the lesions on
separate occasions (Fig 1). Disagreements were resolved by
consensus.
● Type I (focal end-stent group): Lesions are 10 mm
long and are positioned at the proximal or distal mar-
gin (but not both) of the stent. Lesions10 mm long
at both ends of the stent are defined as type I, multi-
focal end-stent.
● Type II (focal intrastent group): Lesions are 10 mm
long and are confined to within the stent(s) without
extending outside the margins. Two or more discrete
lesions 10 mm in length located within the stent are
defined as type II, multifocal intrastent.
● Type III (diffuse intrastent group): Lesions are 10
mm long and are confined to within the stent(s) with-
out extending outside the margins.
● Type IV (diffuse proliferative group): Lesions are10
mm long and extend beyond the margin(s) of the
stent(s).
● Type V (occlusion group). Lesions have no prograde
flow and no lumen is identified.
Angiographic analysis. The angiographic percentage
of stenosis was measured before and after stent deployment in
all patients undergoing CAS and was based on standard tech-
niques using multiple projections. All angiograms were ana-
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detection algorithm (MDQM; MEDCON Telemedicine
Technology, Inc, Livingston,NJ) by an independent observer
whowas blinded to the ultrasound and clinical findings. In 13
arteries, ISR 80% was found and they underwent TLR. In
15 additional ISR lesions, confirmatory angiographywas done
for progressively increasing velocity measurements on ultra-
sound imaging and these were found to be 80% diameter-
reducing lesions. Preprocedural B-mode imaging was com-
pared with angiography in these patients to test the accuracy
of our classification scheme.
Angiographic stenosis was determined using North
Fig 1. A, Schematic images show the five patterns of car
The shaded area represents the stent. B, Representative B
the patterns I through IV.American Symptomatic Carotid Endarterectomy Trial(NASCET) criteria.17 The in-stent least luminal diameter
was compared with the distal nontapering portion of the
internal carotid artery, which served as the reference seg-
ment. Lesion length was measured as the distance from the
proximal shoulder to the distal shoulder of the lesion. The
angiographic lesion length was compared with that ob-
tained by B-mode imaging.
Statistical analysis. Statistical analysis was performed
using GraphPad Prism 3.00 software (GraphPad Software
Inc, San Diego, Calif) and SPSS software (SPSS Inc, Chi-
cago, Ill). Categoric data are presented as percentages and
continuous data as mean  SD. Categoric data were com-
n-stent restenosis based on the introduced classification.
e ultrasound images of in-stent restenosis correspond tootid i
-modpared using the 2 test, and continuous data were com-
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 .05 was considered significant.
The primary end point of the analysis was the associa-
tion of lesion classification with TLR. Univariate variables
with P  .2 were entered into the multivariate logistic
regression model; forward stepping was used to determine
the independent predictors of TLR. Independent variables
were considered significant risk factors at P  .05. To
confirm the accuracy of the classification scheme, ISR le-
sion length measurements derived from duplex ultrasound
imaging were compared with angiographic measurements
using linear regression. Inter-rater agreement on the ultra-
sound classification was assessed by calculating the  statis-
tic; a score of 0.81 to 1.0 was defined as very good agree-
ment.
RESULTS
Patient characteristics. Of the 255 CAS procedures
performed, ISR developed in 85 arteries during a mean
Table I. Baseline patient characteristics
Characteristic*
I, focal end-stent
(n  34)
II, focal
(n 
Distribution 40.0 25
Age, y 73.9  9.4 74.6
Male sex 61.8 63
Diabetes mellitus† 20.6 22
Hypertension 85.3 86
Coronary artery disease 67.6 45
Hypercholesterolemia 64.7 72
Smoking 41.2 45
*Categoric variables expressed as percentage; continuous variables as mean
†P  .02.
Table II. Characteristics of the original treated lesion
Etiology of treated lesion*
I, focal end-stent
(n  34)
In-stent restenosis† 2.94
Primary atherosclerosis‡ 38.2
Post CEA-restenosis 58.8
Severity of treated lesion, % stenosis 81.9
Preprocedure neurologic symptoms 29.4
Details of implanted stents
Stents/lesion 1.1  0.4
Length, mm 28.8  10.3
Types of implanted stents§
Wallstent 50.0
Acculink 50.0
Post-treatment result, % residual stenosis 6.4  7.6
CEA, Carotid endarterectomy.
*Values are expressed as percentages, continuous variables are expressed as
†P  .003.
‡P  .02.
§P  .03.follow-up of 19.3months. Of these 85 ISR lesions classifiedaccording to our proposed scheme, 40% (n  34) were
focal end stent (type I), 25.9% (n  22) were focal intras-
tent (type II), 12.9% (n 11) were diffuse intrastent (type
III), 20% (n 17) were diffuse proliferative, and 1.2% (n
1) developed an occlusion. Inter-rater agreement for the
assignment of lesion type based on ultrasound imaging was
0.88 (very good).
Baseline patient characteristics are presented in Table I.
None of the patients had neurologic symptoms in associa-
tion with the development of ISR. All groups were well
matched with respect to age and sex and for associated
comorbidities such as a history of hypertension, coronary
artery disease, hypercholesterolemia, and smoking. How-
ever, increasing levels of ISR classification were associated
with an increasing prevalence of diabetes mellitus (20.6%,
22.7%, 45.5%, and 52.9% for types I to IV, respectively; 2
trend, 5.4; P  .02).
Lesion characteristics. The severity (degree of steno-
sis) of the original lesion treated with CAS was comparable
erns of in-stent restenosis by type
stent III, diffuse intrastent
(n  11)
IV, diffuse proliferative
(n  17)
12.9 20.0
70.5  6.7 69.2  15.9
63.6 70.6
45.5 52.9
81.8 70.6
45.5 47.1
63.6 64.7
44.2 29.4
.
Patterns of in-stent restenosis by type
cal intrastent
n  22)
III, diffuse intrastent
(n  11)
IV, diffuse proliferative
(n  17)
0 0 41.2
72.7 36.4 23.5
27.3 63.6 35.3
82.5 88.9 83.5
22.7 27.3 23.5
.1  0.3 1.2  0.4 1.3  0.5
.4  8.3 30.0  6.3 28.2  11.7
36.4 27.3 47.1
63.6 72.7 52.9
.1  6.8 6.9  7.3 7.7  8.3
 SDPatt
intra
22)
.9
 6.7
.6
.7
.4
.5
.7
.5
 SDII, fo
(
1
31
7
meanin all ISR classes, as indicated in Table II. The proportion of
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stents used per lesion, and the mean stent length used were
also similar across ISR types. Technical success was
achieved in all patients and no differences were noted in the
angiographic residual stenosis after therapy across all ISR
types.
In this cohort, 37 patients had been treated with a
WallStent and 48 with an Acculink stent. The incidence of
ISR did not vary with the type of stent used or the type of
lesion treated. Univariate analysis indicated a difference in
the patterns of ISR between stent types. Intrastent ISR
patterns (types II and III) occurred more frequently after
placement of Acculink stents compared with WallStents
(P  .03). Univariate analysis also indicated that focal
intrastent (type II) lesions occurred more frequently after
treatment of primary atherosclerotic carotid stenosis com-
pared with treatment for post-CEA restenosis (P  .02).
Finally, 13 patients had recurrent ISR, of which three
were type III lesions and the remaining 10 were type IV.
On univariate analysis, higher levels of ISR classification
were associated with prior ISR (2.9%, 0%, 0%, and 41.2%
for types I to IV, respectively; 2 trend, 13.3; P  .003).
Target lesion revascularization. Endovascular re-
treatment was required in three of 11 patients with type III
ISR, and in 10 of 17 patients with type IV ISR (Table III).
The mean interval between CAS and TLR was 18.2
months. We observed a significant increase in TLR in
association with increasing levels of ISR classification (0%,
0%, 27.3%, and 58.8% for types I to IV, respectively; 2
trend, 29.4; P  .001). Modalities used to treat ISR
included balloon angioplasty, stenting, and cutting balloon
angioplasty alone or in conjunction with stenting. Proce-
dural success was achieved in all these cases, without evi-
dence of any abrupt arterial closure or neurologic events.
Endovascular treatment of ISR afforded similar percentage
diameter residual stenoses in all instances and was not
influenced by ISR class (Table III).
Quantitative angiography vs B-mode imaging
results. Twenty-eight pairs of quantitative angiographic
and B-mode ultrasound measurements were available for
comparative analysis of the geographic distribution of the
Table III. Target lesion revascularization
Variables*
I, focal end-stent
(n  34)
Incidence of TLR, %* 0
Devices used for ISR, No.
Balloon angioplasty 0
Stent 0
Cutting balloon 0
Cutting balloon  stent 0
Post-treatment result, % residual stenosis N/A
TLR, Target lesion revascularization; ISR, in-stent-restenosis; N/A, not ap
*P  .001.ISR lesions. The quantitative angiographic results verifiedthe accuracy of our proposed ultrasound classification of
ISR based on lesion lengthmeasurements (r2 0.82, linear
regression; Fig 2).
Multivariate analysis. We introduced diabetes, coro-
nary artery disease, neurologic symptom status, recurrent
ISR and primary atherosclerosis etiologies, stent type, stent
number, and the pattern of ISR according to the intro-
duced B-mode ultrasound classification in a stepwise mul-
tiple logistic regression model to identify independent pre-
dictors of TLR. The only variables that independently
predicted TLR after CAS were a worsening pattern of ISR
according to our proposed ultrasound classification (odds
ratio, 5.1; P  .003) and the presence of diabetes (odds
ratio, 9.7; P  .04). Coronary artery disease, neurologic
symptoms status, recurrent ISR and primary atherosclerosis
etiologies, stent type, and stent number were not signifi-
cant predictors of TLR in this model.
DISCUSSION
In this study we have described for the first time, to our
knowledge, the various anatomic patterns of ISR observed
after carotid stenting. We have proposed a classification of
Fig 2. Linear regression analysis shows comparison of lesion
length measurement by quantitative angiography vs B-mode ultra-
sound imaging.
Patterns of in-stent restenosis by type
cal intrastent
n  22)
III, diffuse intrastent
(n  11)
IV, diffuse proliferative
(n  17)
0 27.3 58.8
0 1 3
0 1 5
0 0 1
0 1 1
N/A 10.4  6.9 11.9  6.1
le.II, fo
(
plicabthese patterns that uses B-mode ultrasound imaging. The
JOURNAL OF VASCULAR SURGERY
November 2007838 Lal et alscheme depends on the length and the geographic location
of the intimal hyperplasia response in relation to the stent.
The B-mode definition of these patterns correlated with
angiographic assessment, confirming that transcutaneous
ultrasound imaging allowed accurate recognition of the
patterns of ISR occurring after CAS.
The proposed classification (Fig 1) is noninvasive and
can be conveniently applied during each follow-up exami-
nation within a few minutes. It uses straight-forward B-
mode imaging with power Doppler to outline the intimal
hyperplastic lesions, with length measurements performed
on-screen using standard software provided on most cur-
rent ultrasound machines. Results can be printed and saved
for future comparisons during follow-up. The classification
incorporates prior observations that geographic location
and lesion length are important measures of the severity of
the intimal hyperplastic response to coronary stenting.14
We observed that the higher level pattern (diffuse prolifer-
ative, type IV) of ISR after CAS predicted subsequent TLR.
Therefore, the intimal hyperplastic response was most se-
vere in patients who presented with the higher level of the
classification (type IV). We infer that the classification
adequately captures the magnitude of the intimal hyper-
plastic response to CAS.
In a previous study, we reported that ISR occurs in a
significant proportion of patients after CAS.5 Although
most lesions were moderate in severity (40% to 79% steno-
sis), 6.4% were hemodynamically significant (80% steno-
sis) and required reintervention. There is currently no way
to predict which of the low-grade or moderate-grade le-
sions will progress to need reintervention. The present
investigation demonstrates that a classification of ISR pat-
terns can independently predict the development of high-
grade ISR necessitating reintervention.
The only other independent predictor was diabetes,
which is a well-known predictor of early and aggressive
intimal hyperplasia and ISR after coronary stenting.14,18
One report has observed an increased incidence of ISR in
diabetic patients undergoing carotid stenting.19 However,
the relationship between diabetes and the need for repeat
carotid revascularization was not evaluated. Our study con-
firms that diabetes is associated with severe ISR (type IV,
Table I) and that it is an independent predictor of target
vessel failure and subsequent reintervention.
Prior ISR has been hypothesized to predict future
severe recurrent ISR,5 but this has been refuted by oth-
ers.20 Our study provides evidence that prior ISR predis-
poses to severe recurrent ISR (type IV, Table II). The
reason for this exaggerated intimal hyperplastic response to
a reintervention is unknown. In the laboratory, a severe
intimal hyperplastic response can, however, be reproduc-
ibly stimulated in animal models by inducing vascular
injury.21 The continuing presence of an intravascular stent
may afford a similar injury stimulus for intimal hyperplasia
in patients.
The most frequently occurring pattern of ISR in our
cohort was the focal end-stent type (type I, Table I). On
univariate analysis, we observed that most of the intrastentISR lesions (76.2%, type II, Table II) occurred in patients
undergoing CAS for primary atherosclerotic lesions (P 
.02). Conversely, there was a trend towards fewer intrastent
ISR lesions contributed by patients undergoing CAS for
post-CEA restenosis. To our knowledge, this is the first
observation that ISR patterns may differ according to the
etiology of the primary lesion being treated in the carotid
artery. We have previously reported that stenting of the
carotid artery alters arterial wall biomechanical and hemo-
dynamic properties.4 It is possible that stenting alters wall
properties differently in patients with calcified atheroscle-
rotic lesions compared with more compliant fibrotic post-
CEA restenotic lesions, thereby inducing differing patterns
of ISR.
On univariate analysis, the type of stent used for CAS
was also observed to influence the pattern of ISR (P .03,
Table II). Intrastent patterns of ISR (both focal and diffuse,
types II and III) occurred more often in patients treated
with the Acculink stent compared with the WallStent. We
believe this is the first observation that ISR patterns may
vary according to the type of stent deployed in the carotid
artery. The results will require substantiation with a larger
number of patients. Stent biomechanical properties vary
according to their material, geometric design, and dimen-
sions before and after deployment. These factors may in-
duce variable changes in carotid arterial wall biomechan-
ics,22 thereby influencing ISR patterns. Findings from the
current investigation may therefore impact future stent
designs and material selection.
Despite optimal endovascular treatment with similar
final diameter stenosis, some individuals had an enhanced
intimal hyperplastic response to carotid stenting. As stated,
univariate analysis demonstrated that several factors could
influence the magnitude of the intimal hyperplastic re-
sponse and subsequent need for reintervention. These in-
cluded the pattern of ISR after CAS, diabetes, prior ISR,
the etiology of the original lesion, and the type of stent used
(Tables I and II). On multivariate analysis, however, the
pattern of ISR, reflecting the severity of the intimal hyper-
plastic response to injury, independently predicted future
target vessel failure (odds ratio, 5.1; P  .003). Prior ISR
did not independently predict subsequent TLR. This ob-
servation is different from findings in the coronary artery.18
Because prior ISR does result in more severe ISR after CAS,
we infer that the pattern of ISR, influenced by several
mechanisms, determines the risk for target vessel failure and
TLR in the carotid artery.
The proposed classification will facilitate the identifica-
tion of patients with severe patterns of ISR (type IV)
noninvasively by ultrasound imaging. This will enable early
selection of these patients for aggressive monitoring or
additional therapy in conjunction with stenting. Endovas-
cular treatment was successfully achieved without compli-
cations in all instances of reintervention for high-grade
(80%) ISR (Table III). We have previously reported that
post-CAS ISR is a neointimal hyperplastic lesion that is not
associated with the same risk of atheroembolic complica-
tions as in primary atherosclerotic lesions.5 The multiple
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mary stenting or a combination of these) indicate an ab-
sence of consensus on the optimal method of treatment.
Intravascular radiation23 and local24 or systemic25 pharma-
cologic agents are under active investigation in high-risk
coronary ISR patients and may prove beneficial in their
treatment. Early and appropriate identification and treat-
ment of these high-risk ISR patients using our ultrasound
classification may improve cost-effective patient manage-
ment and help develop novel revascularization strategies.
Limitations. This retrospective analysis is subject to
the limitations related to such an investigation. Data were
retrieved from our CAS Quality Assurance Database. The
database is updated prospectively and incorporates the
same information for all carotid stenosis patients undergo-
ing endovascular interventions, regardless of clinical indi-
cations and outcomes. Because selective carotid angiogra-
phy is associated with a risk of atheroembolic stroke,26 this
modality was not used for routine follow-up. Duplex ultra-
sonography is readily available at our certified vascular
laboratory. It produces high-resolution images of this rel-
atively superficial artery, is inexpensive,12,27 and is therefore
ideally suited for the follow-up of patients undergoing
CAS.5 Only persistently high velocities indicative of ISR
80%, or a recent rapid increase in velocities, were indica-
tions for diagnostic angiography. Although intravascular
ultrasonography may provide accurate information on inti-
mal hyperplastic lesions, the risk of atheroembolic stroke
from additional instrumentation across the treated arterial
segment has resulted in limited use of this modality for
follow-up by most CAS operators.
This analysis includes 14 patients that underwent CAS
without antiembolic protection early in our experience. To
the best of our knowledge, however, use of an antiembolic
device does not alter ISR and should therefore not influ-
ence results of this study.
Carotid occlusion is a rare outcome after CAS5 and
occurred in only one patient from this series of 255 CAS
procedures; therefore, it is not possible to determine pre-
dictors for this outcome. Of note, this patient remained
asymptomatic despite the occlusion.
CONCLUSION
ISR after CAS presents with various ultrasound pat-
terns that provide important prognostic information. As
determined by the classification introduced in this study,
focal end-stent, focal intrastent, diffuse intrastent, diffuse
proliferative, and occluded ISR represent a spectrum of
increasing intimal hyperplastic response to CAS. The pat-
tern of ISR and a history of diabetes are important deter-
minants of long-term outcome after CAS. In contrast,
other comorbidities, prior neurologic symptom status, and
immediate technical results appear to be less important.
These observations imply that intrinsic biologic character-
istics (ISR pattern and diabetes) have more influence over
the long-term results of CAS than the immediate technical
results of the treatment. The classification also offers an
opportunity for the early identification of high-risk patientsfor intensive monitoring and treatment. By providing a
standardized method of describing restenotic lesions, it will
also facilitate further investigations into adjunctive treat-
ments for ISR and improved stent design.
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